)
Clearpoint Neuro (CLPT) investor relations material
Clearpoint Neuro Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company overview and business model
Commercial-stage medical-device business spanning minimally invasive neurosurgery, neurocritical care and biologics/drug-delivery services for pharmaceutical and biotech partners.
ClearPoint system guides electrode, biopsy-needle and laser-catheter placement and brain infusions; SmartFrame OR and 2025 navigation software support operating-room procedures.
IRRAflow, added through the 2025 IRRAS acquisition, combines intracranial irrigation, drainage and pressure monitoring; ClearPoint Prism is commercialized under exclusive global neuro rights from Clinical Laserthermia Systems AB.
More than 60 biologics and drug-delivery customers are evaluating products or services for brain gene- and cell-therapy trials; FDA authorized SmartFlow cannula marketing for an AADC gene therapy in 2024.
Financial performance and metrics
Net tangible book value at September 30, 2026 was $7.4m, or $0.23/share; illustrative post-offering value was $104.0m, or $2.37/share, assuming $100m gross proceeds at $8.48/share.
Under that illustration, new investors face $6.11/share immediate dilution; existing shares were 32,051,494 at September 30, 2026, excluding 2,497,985 option/RSU shares and 1,724,125 shares available for future awards.
Use of proceeds and capital allocation
ATM net proceeds, if any, are intended for general corporate purposes, including working capital, capex, R&D, clinical trials, commercialization, acquisitions, in-licensing and complementary investments; management retains broad discretion.
Pending use, proceeds may be invested in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed U.S. government obligations.
- Biologics growth and stronger margins partly offset COVID-driven procedural and equipment declines.CLPT
Q2 2020 - Revenue rose 38% as record case volume supported FY2021 growth guidance.CLPT
Q2 2021 - 2026 revenue estimated at $48M–$50M; longer-term plans target $500M.CLPT
Investor presentation - Q3 revenue rose 36%, but net losses widened as 2026 guidance reached $48M–$50M.CLPT
Q3 2026 - Q2 2026 revenue up 18% to $10.9M; net loss widened; 2026 guidance set at $48–$52M.CLPT
Q2 2026 - Q1 2026 revenue up 43% to $12.1M, margin at 64%, but net loss widened on higher expenses.CLPT
Q1 2026 - Q3 revenue up 9% to $8.9M, gross margin at 63%, IRRAS acquisition to drive future growth.CLPT
Q3 2025 - Q2 revenue up 32% to $7.9M, gross margin at 63%, and 2024 guidance raised to $33M.CLPT
Q2 2024 - 2024 revenue rose 31% to $31.4M; 2025 guidance targets up to 31% growth and global expansion.CLPT
Q4 2024
)
)
)
)
)
)
)
)